Cara Therapeutics Inc
NASDAQ:TVRD
ROA
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Peer Comparison
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Cara Therapeutics Inc
NASDAQ:CARA
|
83.4m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -5 431 900% |
| 30th Percentile | -10.9% |
| Median | 0.7% |
| 70th Percentile | 4.2% |
| Max | 251 842.7% |
Other Profitability Ratios
Cara Therapeutics Inc
Glance View
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.
See Also
ROA is calculated by dividing the Net Income by the Avg Total Assets.
The current ROA for Cara Therapeutics Inc is -83.5%, which is below its 3-year median of -82.6%.
Over the last 3 years, Cara Therapeutics Inc’s ROA has decreased from -34.1% to -83.5%. During this period, it reached a low of -114.7% on Sep 30, 2024 and a high of -29.6% on Jun 30, 2022.
